

**HSD17B7 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP6760a****Specification**

---

**HSD17B7 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [P56937](#)**HSD17B7 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 51478**Other Names**3-keto-steroid reductase, 17-beta-hydroxysteroid dehydrogenase 7, 17-beta-HSD 7, Estradiol  
17-beta-dehydrogenase 7, HSD17B7**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6760a](/products/AP6760a) was selected from the N-term region of human HSD17B7. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**HSD17B7 Antibody (N-term) Blocking Peptide - Protein Information****Name** HSD17B7**Synonyms** 17HSD7 {ECO:0000303|PubMed:12732193}, SD**Function**

Bifunctional enzyme involved in steroid-hormone metabolism and cholesterol biosynthesis (PubMed: [12574203](http://www.uniprot.org/citations/12574203), PubMed: [12732193](http://www.uniprot.org/citations/12732193), PubMed: [12829805](http://www.uniprot.org/citations/12829805), PubMed: [20659585](http://www.uniprot.org/citations/20659585), PubMed: [19772289](http://www.uniprot.org/citations/19772289), PubMed: [11165030](http://www.uniprot.org/citations/11165030)). Catalyzes the NADP(H)-dependent reduction of estrogens and androgens and regulates the biological potency of these steroids. Converts estrone (E1) to a more potent estrogen,

17beta-estradiol (E2) (PubMed:<a href="http://www.uniprot.org/citations/12574203" target="\_blank">12574203</a>, PubMed:<a href="http://www.uniprot.org/citations/12732193" target="\_blank">12732193</a>, PubMed:<a href="http://www.uniprot.org/citations/19772289" target="\_blank">19772289</a>). Converts dihydrotestosterone (DHT) to its inactive form 5a-androstane-3b,17b- diol (PubMed:<a href="http://www.uniprot.org/citations/12574203" target="\_blank">12574203</a>, PubMed:<a href="http://www.uniprot.org/citations/12732193" target="\_blank">12732193</a>, PubMed:<a href="http://www.uniprot.org/citations/19772289" target="\_blank">19772289</a>). Converts moderately progesterone to 3beta-hydroxypregn-4-ene-20-one, leading to its inactivation (PubMed:<a href="http://www.uniprot.org/citations/12574203" target="\_blank">12574203</a>, PubMed:<a href="http://www.uniprot.org/citations/12732193" target="\_blank">12732193</a>). Additionally, participates in the post-squalene cholesterol biosynthesis, as a 3- ketosteroid reductase (PubMed:<a href="http://www.uniprot.org/citations/12829805" target="\_blank">12829805</a>, PubMed:<a href="http://www.uniprot.org/citations/20659585" target="\_blank">20659585</a>, PubMed:<a href="http://www.uniprot.org/citations/11165030" target="\_blank">11165030</a>).

### **Cellular Location**

Endoplasmic reticulum membrane; Single-pass membrane protein

### **Tissue Location**

Highly expressed in adrenal gland, liver, lung and thymus. Expressed in breast, ovaries, pituitary gland, pregnant uterus, prostate, kidney, lymph node, small intestine, spinal cord and trachea  
Weakly expressed in all other tissues tested

### **HSD17B7 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **HSD17B7 Antibody (N-term) Blocking Peptide - Images**

### **HSD17B7 Antibody (N-term) Blocking Peptide - Background**

HSD17B7 oxidizes or reduces estrogens and androgens in mammals and regulates the biologic potency of these steroids.

### **HSD17B7 Antibody (N-term) Blocking Peptide - References**

Plourde,M., et.al.,J. Steroid Biochem. Mol. Biol. 116 (3-5), 134-153 (2009)